The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials

Heart Failure Reviews
Bo XiongJing Huang

Abstract

A comprehensive evaluation of the benefits of tolvaptan for the management of heart failure (HF) is lacking. The objective of this meta-analysis was to assess the short-term and long-term effects of tolvaptan in patients with HF. Articles were searched from PubMed, MEDLINE and Cochrane Library before March 31, 2015. Randomized controlled trials enrolling adult HF patients and reporting the all-cause mortality, cardiac events, body weight change or changes of serum electrolytes including sodium, potassium and creatinine were included in our meta-analysis. Ten studies covering 5574 patients met the inclusion criteria. Based on the data of meta-analysis, tolvaptan had no impact on the all-cause mortality [relative risk (RR) 0.96; 95 % confidence interval (CI) 0.87-1.06; P = 0.40] and incidence of cardiac events (RR 1.03; 95 % CI 0.96-1.11; P = 0.40) of HF patients. Furthermore, in comparison with control treatments, tolvaptan significantly decreased the body weight [weight mean difference (WMD), -0.87; 95 % CI -1.03 to -0.71; P < 0.001] and statistically increased serum sodium (WMD, 2.58; 95 % CI -1.83 to 3.33; P < 0.001) without any change in serum potassium (WMD, 0.01; 95 % CI -0.03 to 0.05; P = 0.577). However, serum creatinine...Continue Reading

References

Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Nov 16, 2005·Journal of the American College of Cardiology·Steven R Goldsmith, Mihai Gheorghiade
Sep 27, 2006·European Heart Journal·Markku S NieminenUNKNOWN Heart Failure Association, European Society of Cardiology
Nov 9, 2006·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN OPTIMIZE-HF Investigators and Coordinators
Nov 16, 2006·The New England Journal of Medicine·Robert W SchrierUNKNOWN SALT Investigators
Nov 23, 2006·The American Journal of Medicine·Mihai GheorghiadeJohn Burnett
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Oct 10, 2007·Journal of Cardiac Failure·Kevin DammanHans L Hillege
Jul 23, 2009·Annals of Internal Medicine·David MoherUNKNOWN PRISMA Group
Aug 17, 2010·Drug Discovery Today·Punniyakoti T VeeraveeduKenichi Watanabe
Oct 30, 2010·Journal of the American College of Cardiology·Jacob C JentzerAdrian F Hernandez
Jul 16, 2011·Journal of the American College of Cardiology·Jeffrey M TestaniStephen E Kimmel
Sep 18, 2012·Circulation. Heart Failure·Takanori YamazakiMinoru Yoshiyama
Aug 31, 2013·Circulation Research·Véronique L Roger
Oct 22, 2013·Journal of Clinical Pharmacology·Satoshi SuzukiUNKNOWN AVCMA investigators
Jan 10, 2014·Journal of Pharmacological Sciences·Yasukatsu IzumiHiroshi Iwao
Jul 30, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·San-e Ishikawa

❮ Previous
Next ❯

Citations

Jul 11, 2016·European Journal of Clinical Pharmacology·Keita HiraiKunihiko Itoh
Jun 20, 2017·Drug Discoveries & Therapeutics·Shunsuke KiuchiTakanori Ikeda
Aug 3, 2018·Expert Opinion on Pharmacotherapy·Theodosios FilippatosGeorge Liamis
Oct 30, 2018·International Heart Journal·Koichiro KinugawaTakayuki Inomata
Sep 14, 2018·Internal Medicine·Shunsuke Kiuchi, Takanori Ikeda
Jan 15, 2019·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Kazuhiko Kido, Maya Guglin
Dec 28, 2019·Current Pharmaceutical Design·Carmelo ButtàAntonio Pinto
Sep 13, 2018·Journal of Clinical Medicine·Francisco Herrera-GómezF Javier Álvarez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.